Calprotectin in inflammatory bowel disease

Khaki‐Khatibi, Fatemeh; Qujeq, Durdi; Kashifard, Mehrdad; Moein, Soheila; Maniati, Mahmood; Vaghari‐Tabari, Mostafa

doi:10.1016/j.cca.2020.08.025

Cited by 68 publications

(72 citation statements)

References 121 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 24 The main advantage of FC is the derivation from direct mucosal contact that allows the detection of intestinal inflammatory conditions more precisely than serum biomarkers. 25 FC is becoming the most useful non-invasive tool for monitoring the mucosal inflammation and assessing treatment response in IBD.…”

Section: Discussionmentioning

confidence: 99%

“… 12 Calprotectin concentration in feces is six times higher than in plasma, and FC may remain stable for up to 1 week at room temperature, a highly desirable quality for a biomarker of intestinal inflammation. 13 Previous studies 14 revealed that FC can predict endoscopic inflammation, although optimal cut-off values vary across studies. Growing evidence shows that FC can be used as a biomarker to assess endoscopic and histologic remission in inflammatory bowel disease (IBD).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Zou

Wang

Glitza

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundImmune-mediated diarrhea and colitis (IMDC) is currently diagnosed and monitored by evaluating clinical symptoms. Deep remission is determined by endoscopic and histologic evaluation of the disease process. However, repeating these invasive procedures frequently can become cumbersome. We sought to assess the role of fecal calprotectin (FC) concentration as a non-invasive biomarker of endoscopic or histologic remission.MethodsWe performed a retrospective study of patients with IMDC who were tested for FC at IMDC onset and after IMDC treatment between June 2016 and March 2020. Patient demographics, clinical variables, and FC data were collected and analyzed to determine the optimal cut-off FC concentration to predict endoscopic and histologic remission.ResultsOur sample comprised 77 patients with a median age of 62 years; 66% were male and 94% were Caucasian. Sixty-five patients (84%) achieved clinical remission, 46 (60%) achieved endoscopic remission, and 24 (31%) achieved histologic remission after IMDC treatment. FC concentrations decreased from the time of IMDC onset to the end of treatment (p<0.001). High FC concentrations were associated with evident endoscopic inflammation (p=0.003) and acute/chronic active colitis (p=0.025) which positively correlated with the Mayo Endoscopic Subscore (r=0.615, p=0.001) at the time of IMDC onset. In patients who achieved endoscopic remission after treatment, a significantly lower FC concentration was observed at IMDC onset (p=0.006) and after treatment (p<0.001) compared with those without endoscopic remission. The cut-off FC concentration to predict endoscopic remission was ≤116 μg/g and for histologic remission ≤80 μg/g; these cut-offs had optimal specificity (94% and 85%, respectively) and positive predictive value (0.91 and 0.38, respectively).ConclusionsFC concentration may serve as a non-invasive biomarker to predict endoscopic and histologic remission in patients receiving treatment for IMDC, minimizing the need for frequent invasive endoscopies. Future prospective studies are needed to provide further insight on the role of this marker in disease surveillance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Zou

Wang

Glitza

et al. 2021

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Interestingly, S100-A8 and A9 and Dermcidin were found consistently upregulated in the samples of STIR+ muscles both by DIA and DDA. S100-A8 and A9 are calcium binding proteins actively secreted by myeloid cells (both neutrophils and monocytes), supposed to play a pivotal role in the pathogenesis of rheumatoid arthritis, inflammatory bowel disease and cystic fibrosis [ 19 , 20 ]. They constitute a heterodimer, also known as calprotectin, which may act as a damage-associated molecular pattern (DAMP) [ 21 ] able to activate innate immune pathways through stimulation of Toll-like receptor 4, therefore constituting a key molecule to trigger stress and inflammatory responses also in cancer [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy

Carregari

Monforte

Maio

et al. 2020

IJMS

View full text Add to dashboard Cite

Facioscapulohumeral muscular dystrophy (FSHD) is caused by a complex epigenetic mechanism finally leading to the misexpression of DUX4 in skeletal muscle. Detecting DUX4 and quantifying disease progression in FSHD is extremely challenging, thus increasing the need for surrogate biomarkers. We applied a shotgun proteomic approach with two different setups to analyze the protein repertoire of interstitial fluids obtained from 20 muscles in different disease stages classified by magnetic resonance imaging (MRI) and serum samples from 10 FSHD patients. A total of 1156 proteins were identified in the microdialysates by data independent acquisition, 130 of which only found in muscles in active disease stage. Proteomic profiles were able to distinguish FSHD patients from controls. Two innate immunity mediators (S100-A8 and A9) and Dermcidin were upregulated in muscles with active disease and selectively present in the sera of FSHD patients. Structural muscle and plasminogen pathway proteins were downregulated. Together with the upstream inhibition of myogenic factors, this suggests defective muscle regeneration and increased fibrosis in early/active FSHD. Our MRI targeted exploratory approach confirmed that inflammatory response has a prominent role, together with impaired muscle regeneration, before clear muscle wasting occurs. We also identified three proteins as tissue and possibly circulating biomarkers in FSHD.

show abstract

“…An increase in fecal calprotectin has been detected in other conditions involving gut inflammation, such as inflammatory bowel diseases 89 . Some studies 90,91 have suggested an increase in this parameter in non‐IgE‐mediated food allergy, including FPIES 92 .…”

Section: Diagnosismentioning

confidence: 99%

'Diagnosing food protein‐induced enterocolitis syndrome'

Barni

Vazquez‐Ortiz

Giovannini

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Food protein-induced enterocolitis syndrome is still a mysterious disease, pathogenically poorly characterized, although the first FPIES case has been described in 1967. Mainly, food protein-induced enterocolitis syndrome diagnosis is based on clinical history. The oral food challenge remains the gold standard to confirm the diagnosis, especially in particular situations. Although there are no diagnostic laboratory or imaging tests which are specific for diagnosis, they could, however, sometimes be helpful to rule out clinical conditions which are similar to food protein-induced enterocolitis syndrome reactions. The purpose of this review is to define the clinical features of FPIES and to summarize the current available tools for the diagnosis of FPIES. This review is intended to be a practical guide for the clinician facing a patient with food protein-induced enterocolitis syndrome avoiding delayed diagnosis with unnecessary laboratory tests and detrimental treatments. Moreover, it highlights the unmet needs in diagnosis that require urgent attention from the scientific community to improve the management of patients with FPIES.

show abstract

Calprotectin in inflammatory bowel disease

Cited by 68 publications

References 121 publications

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy

'Diagnosing food protein‐induced enterocolitis syndrome'

Contact Info

Product

Resources

About